Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erasca, Inc. stock logo
ERAS
Erasca
$13.89
-8.1%
$14.89
$2.71
▼
$24.28
$5.30B0.685.09 million shs8.79 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$105.88
+0.3%
$122.50
$41.50
▼
$166.48
$4.75B2.86899,758 shs699,824 shs
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$3.91
+1.9%
$5.02
$3.79
▼
$9.75
$1.36B1.735.27 million shs5.75 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$60.36
-1.0%
$63.78
$58.80
▼
$90.87
$5.09B0.521.07 million shs1.12 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erasca, Inc. stock logo
ERAS
Erasca
-3.51%-3.20%+12.85%-16.52%+485.66%
GRAIL, Inc. stock logo
GRAL
GRAIL
-8.88%-17.55%-10.36%+48.96%+32.61%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-3.15%-10.96%-12.76%-44.27%-20.36%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-3.97%-6.24%+2.92%-16.05%-19.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erasca, Inc. stock logo
ERAS
Erasca
$13.89
-8.1%
$14.89
$2.71
▼
$24.28
$5.30B0.685.09 million shs8.79 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$105.88
+0.3%
$122.50
$41.50
▼
$166.48
$4.75B2.86899,758 shs699,824 shs
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$3.91
+1.9%
$5.02
$3.79
▼
$9.75
$1.36B1.735.27 million shs5.75 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$60.36
-1.0%
$63.78
$58.80
▼
$90.87
$5.09B0.521.07 million shs1.12 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erasca, Inc. stock logo
ERAS
Erasca
-3.51%-3.20%+12.85%-16.52%+485.66%
GRAIL, Inc. stock logo
GRAL
GRAIL
-8.88%-17.55%-10.36%+48.96%+32.61%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-3.15%-10.96%-12.76%-44.27%-20.36%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-3.97%-6.24%+2.92%-16.05%-19.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Erasca, Inc. stock logo
ERAS
Erasca
2.67
Moderate Buy$23.1766.79% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$128.8021.65% Upside
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
2.67
Moderate Buy$12.89229.39% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.73
Moderate Buy$99.2364.40% Upside

Current Analyst Ratings Breakdown

Latest NUVB, ERAS, GRAL, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Erasca, Inc. stock logo
ERAS
Erasca
Initiated CoverageOutperform$35.00
11/17/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingBuy$21.00
11/10/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Boost Price TargetNeutral$74.00 ➝ $130.00
11/5/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Boost Price TargetSector Perform$84.00 ➝ $100.00
11/5/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Lower Price TargetOutperform$20.00 ➝ $17.00
11/2/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetBuy$108.00 ➝ $109.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetBuy$90.00 ➝ $95.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetOverweight$109.00 ➝ $112.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetSector Perform$75.00 ➝ $77.00
10/20/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Set Price Target$106.00
10/19/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingMarket Outperform
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$2.61 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M32.35N/AN/A$54.57 per share1.94
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$62.90M21.96N/AN/A$0.65 per share6.02
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B2.91$8.68 per share6.95($2.29) per share-26.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.99N/AN/AN/AN/A-31.63%-27.57%N/A
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.50N/AN/AN/A-243.80%-16.13%-14.38%N/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$204.63M-$0.40N/AN/AN/A-67.38%-45.69%-18.54%N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$1.40N/A21.714.47-9.17%N/A-0.10%N/A

Latest NUVB, ERAS, GRAL, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1301-$0.15-$0.0199-$0.15N/AN/A
11/4/2026Q3 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.45-$2.21+$0.24-$2.21$44.21 million$37.54 million
11/4/2026Q3 2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$0.1236-$0.12+$0.0036-$0.12$34.39 million$44.95 million
10/29/2026Q3 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.1434-$0.62-$0.7634-$0.62$306.43 million$357.81 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Erasca, Inc. stock logo
ERAS
Erasca
N/A
14.89
14.89
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
8.93
8.93
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
1.23
7.45
7.30
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.27
3.13

Institutional Ownership

CompanyInstitutional Ownership
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
61.67%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Erasca, Inc. stock logo
ERAS
Erasca
14.20%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
30.11%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Erasca, Inc. stock logo
ERAS
Erasca
103350.96 million300.10 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.96 million44.14 millionOptionable
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
310353.02 million246.72 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
99183.54 million79.12 millionOptionable

Recent News About These Companies

PTC Therapeutics Earnings Call Highlights Sephience Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Erasca stock logo

Erasca NASDAQ:ERAS

$13.89 -1.22 (-8.07%)
Closing price 04:00 PM Eastern
Extended Trading
$14.29 +0.40 (+2.89%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$105.88 +0.28 (+0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$107.75 +1.87 (+1.76%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Nuvation Bio stock logo

Nuvation Bio NYSE:NUVB

$3.91 +0.07 (+1.90%)
Closing price 03:59 PM Eastern
Extended Trading
$3.93 +0.01 (+0.36%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$60.36 -0.61 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$60.45 +0.09 (+0.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.